Overview

Safety Study of Intranasal Etripamil for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia (PSVT). NODE-302

Status:
Completed

Trial end date:
2020-11-13

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to evaluate the safety of etripamil nasal spray (NS) 70 mg when self-administered by patients with an episode of Paroxysmal Supraventricular Tachycardia in an outpatient setting (i.e., without medical supervision).

Phase:

Phase 3

Details

Lead Sponsor:

Milestone Pharmaceuticals Inc.

Collaborator:

Medpace, Inc.

Treatments:

Etripamil